このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ステージ2タイプ1糖尿病の日本の参加者におけるテプリズマブの有効性と安全性 (KIBOU-T1D)

2026年11月6日 更新者:Sanofi

ステージ2型糖尿病で8〜34歳の日本の小児および成人の参加者の治療におけるテプリズマブの有効性と安全性:多施設、無作為化、非盲検、対照研究。

This is a parallel, Phase 2, two-arm study to assess the efficacy and safety of 14-days intravenous (IV) infusion of teplizumab treatment.

Teplizumab has been approved by FDA to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. The dose regimen of teplizumab in this study is consistent with the regimen approved by US FDA.

Given prior clinical studies conducted in Western countries, this design is appropriate to assess the efficacy, safety and tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity of a 14-day IV infusion regimen of teplizumab in Japanese Stage 2 T1D participants aged 1 to 34 years.

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

Total study duration is approximately 756 days.

研究の種類

介入

入学 (実際)

5

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Fukuoka、日本、812-0025
        • Investigational Site Number : 3920017
      • Kyoto、日本、606-8507
        • Investigational Site Number : 3920016
      • Nagasaki、日本、852-8501
        • Investigational Site Number : 3920014
      • Osaka、日本、545-8586
        • Investigational Site Number : 3920004
      • Tokyo、日本、101-8309
        • Investigational Site Number : 3920020
      • Tokyo、日本、162-8666
        • Investigational Site Number : 3920003
    • Chiba
      • Ichikawa、Chiba、日本、272-0827
        • Investigational Site Number : 3920015
    • Gunma
      • Maebashi、Gunma、日本、371-8511
        • Investigational Site Number : 3920011
    • Hokkaido
      • Sapporo、Hokkaido、日本、060-8543
        • Investigational Site Number : 3920006
    • Hyōgo
      • Kobe、Hyōgo、日本、650-0017
        • Investigational Site Number : 3920018
    • Ishikawa-ken
      • Kanazawa、Ishikawa-ken、日本、920-8641
        • Investigational Site Number : 3920009
    • Iwate
      • Yahaba、Iwate、日本、028-3695
        • Investigational Site Number : 3920007
    • Kanagawa
      • Yokohama、Kanagawa、日本、222-0036
        • Investigational Site Number : 3920019
    • Saitama
      • Iruma、Saitama、日本、350-0495
        • Investigational Site Number : 3920001
    • Yamanashi
      • Chūō、Yamanashi、日本、409-3898
        • Investigational Site Number : 3920010

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1年~34年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Male or female Japanese participant, 1 (inclusive) to 34 years (inclusive) of age, at the time of signing the informed consent. Japanese: born in Japan or ethnic Japanese born outside of Japan, and a descendent of 4 ethnic Japanese grandparents who were all born in Japan.
  • Confirmed diagnosis of Stage 2 T1D based on following criteria:
  • Participant is positive for 2 or more T1D related auto-antibodies (confirmed by written medical history and/or obtained at study screening). The autoantibodies that are to be confirmed are anti-GAD (glutamic acid decarboxylase), anti-IA2 (insulinoma-associated antigen 2), anti-insulin, anti-ZnT8 (zinc transporter 8), and/or ICA (islet cell antibody).
  • Oral glucose tolerance test (OGTT) or blood HbA1c confirms the participant has dysglycemia without overt hyperglycemia.
  • Participant must be in good health (except for being Stage 2 T1D) as determined by medical e)valuation including medical history, physical examination, laboratory tests, and electrocardiogram (ECG) XE " ECG " \f Abbreviation \t "electrocardiogram" .
  • Participant is up to date with routine age-appropriate immunizations according to current local specific guideline prior to randomization.
  • Female participants should use contraceptives consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • A female participant is considered fertile (woman of childbearing potential - WOCBP) from the time of menarche until becoming postmenopausal unless permanently sterile. Female participants are eligible to participate if one of the following conditions applies:
  • Is a woman of nonchildbearing potential (WONCBP) OR
  • Is a WOCBP and agrees to keep abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, or use other highly effective contraceptive method, from signing of the informed consent to at least 3 months and 2 weeks after randomization and agrees not to donate or cryopreserve eggs (ova, oocytes) for the purpose of reproduction during this period.

A WOCBP must have at least a negative highly sensitive pregnancy test within 48 hours before the administration of study intervention.

If a urine test cannot be confirmed as negative (eg, an ambiguous result), a blood pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.

Participants are excluded from the study if any of the following criteria apply:

  • Any presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, dermatologic, hepatic, renal, metabolic (except Stage 2 T1D), hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.
  • Participant has clinical signs and symptoms consistent with COVID19, eg, fever, dry cough, dyspnea, loss of taste and smell, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening. Participant who had severe course of COVID-19 (ie, hospitalization, extracorporeal membrane oxygenation, mechanically ventilated).
  • For participant ≥18 years, blood donation of 400 mL within 12 weeks (male) or 16 weeks (female), 200 mL within 4 weeks or apheresis donation within 2 weeks before randomization; for participant <18 years, blood donation of any volume within 16 weeks before randomization; for any participant, blood transfusion (any volume) within 2 months before randomization.
  • Presence or history of drug hypersensitivity to any biologic medication, or clinically significant allergic disease as diagnosed and treated by a physician. Participants with known hypersensitivity to teplizumab or components of the teplizumab injection (including sodium phosphate, sodium chloride, polysorbate 80).
  • Participants with a history of active or latent or inactive tuberculosis (TB), including chest X-ray consistent with TB, regardless of treatment, or have a positive QuantiFERON-TB Gold test or T-SPOT TB test at screening.
  • At screening, participant has laboratory or clinical evidence of acute or clinically active infection with Epstein Barr virus (EBV), or history of infectious mononucleosis within 3 months before enrollment.
  • At screening, participant has laboratory or clinical evidence of acute or clinically active infection with cytomegalovirus (CMV).
  • Participants with a history of invasive opportunistic infections, such as histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, pneumocystis jirovecii, aspergillosis, irrespective of resolution.
  • Participants have other autoimmune diseases, except clinically stable autoimmune thyroid disease, or celiac disease.
  • Participants with a history of malignancy occurring within 5 years before randomization (except successfully treated carcinoma in situ of the cervix, or adequately treated nonmetastatic squamous cell or basal cell carcinoma of the skin).
  • Participants with fever (temperature ≥38.0°C) within 48 hours before randomization; or with chronic persistent or recurring infection(s) requiring active treatment with antibiotics, antiviral or antifungals within 4 weeks before randomization; or with other frequent recurrent infections deemed unacceptable as per Investigator's judgement.
  • If female, pregnancy (defined as positive blood or urine pregnancy test) or breast-feeding.
  • Participant has recent or planned vaccinations as follows:
  • Live vaccines: within 8 weeks before randomization, and/or within 54 weeks after randomization.
  • Non-live vaccines: any initial non-live vaccination within 2 weeks before randomization, and/or within 8 weeks after randomization.
  • Participant has a current or prior (within 30 days before randomization) treatment that is known to cause a significant, ongoing change in the course of T1D or immunologic status, including high dose, inhaled, extensive topical, or systemic glucocorticoids.
  • Participant has a current or prior (within 30 days before randomization) treatment that is known to significantly influence glucose tolerance (anti-hyperglycemic agents, atypical antipsychotics, diphenylhydantoin, niacin etc.).
  • Participant has received any anti-CD3 (cluster of differentiation 3) antibody treatment (including teplizumab) before randomization.
  • Participant who has received any biologic therapy within five half-lives of the therapy or within 6 months before randomization whichever is longer, or plan to receive any biologic therapy within 6 weeks after randomization.
  • Any participant enrolled or having participated, in this or any other clinical study involving an investigational medicinal product (IMP) or in any other type of medical research and is still in the exclusion period according to applicable regulations (eg, having received an IMP of new active pharmaceutical ingredient (API) within 4 months or that of an approved API within 3 months before the administration of this study's IMP).
  • Participant has any of the following hematologic parameters before randomization:
  • Lymphocyte count <1.0 ×109/L.
  • Neutrophil count <1.5 ×109/L.
  • Platelet count <150 ×109/L.
  • Hemoglobin <100 g/L.
  • Participant has any of the following liver function test abnormalities before randomization:
  • AST >2 × ULN (upper limit normal).
  • ALT >2 × ULN.
  • Total bilirubin >1.5 × ULN with the exception of participants with the diagnosis of Gilbert's syndrome who may be eligible provided they have no other causes leading to hyperbilirubinemia.
  • Positive result on any of the following tests:
  • Hepatitis B surface antigen or hepatitis B core antibody confirmed by positive HBV-DNA (hepatitis B virus DNA).
  • Anti-hepatitis C virus antibody confirmed by positive HCV-RNA (hepatitis C virus RNA).
  • Human immunodeficiency virus antigen/ antibodies.
  • Positive SARS-CoV-2 test.
  • Participant who has contraindications or known allergy to both nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, or anti-histamines and in the opinion of the Investigator, cannot participate in the study.
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Teplizumab

Participants will receive Teplizumab via IV infusion

Pharmaceutical form:Solution for injection-Route of administration:Intravenous infusion

他の名前:
  • SAR446681
  • Tzield
介入なし:Control

Participants will receive no treatment in the control group

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
米国糖尿病協会の基準に基づくステージ 3 の 1 型糖尿病の参加者数
時間枠:ベースラインから 104 週目まで
ベースラインから 104 週目まで
C ペプチドの曲線下面積 (AUC) のベースラインからの変化
時間枠:ベースラインから104週まで
ベースラインから104週まで
Change from baseline in AUC of endogenous insulin
時間枠:From baseline up to Week 104
From baseline up to Week 104
Number of participants with TEAEs, SAEs, AEs leading to permanent study intervention- or study discontinuation; AEs of special interest; number of participants with clinically significant changes in vital signs, ECG, and/or safety laboratory test
時間枠:Throughout the study, approximately 756 days

TEAE: treatment-emerged adverse event; SAE: serious adverse event; AE: adverse event

Throughout the study, approximately 756 days

二次結果の測定

結果測定
時間枠
経口ブドウ糖負荷試験による空腹時血漿グルコース(FPG)のベースラインからの変化
時間枠:ベースラインから 104 週目まで
ベースラインから 104 週目まで
経口ブドウ糖負荷試験による 2 時間血漿グルコースのベースラインからの変化
時間枠:ベースラインから104週まで
ベースラインから104週まで
ヘモグロビンA1cのベースラインからの変化(HBA1C)
時間枠:ベースラインから104週まで
ベースラインから104週まで
テプリズマブの血清濃度
時間枠:1日目から28日目まで
1日目から28日目まで
抗薬物抗体を持つ参加者の数
時間枠:ベースラインから 104 週目まで
ベースラインから 104 週目まで
中和抗体を持つ参加者の数
時間枠:ベースラインから 104 週目まで
ベースラインから 104 週目まで

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年7月25日

一次修了 (推定)

2028年3月6日

研究の完了 (推定)

2028年3月6日

試験登録日

最初に提出

2025年1月20日

QC基準を満たした最初の提出物

2025年1月20日

最初の投稿 (実際)

2025年1月24日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • ACT18487
  • U1111-1308-1324 (レジストリ識別子:ICTRP)
  • jRCT2031240637 (レジストリ識別子:JRCT)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する